Nowell Fine, MD SM PRCPC
Director of Echocardiography, Heart Failure Cardiologist
Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary
University of Calgary
With the development of new therapeutics in cardiac amyloidosis, interest has signficantly increased in this disease which was considered until very recently as incurable. However, although a few recent reports suggest that the incidence of the disease is higher than initially thought, its diagnosis remains problematic. While definite diagnosis is made through cardiac biopsy, non invasive imaging is the first tool to screen patients and raise the diagnosis.
This workshop endorsed by the Canadian Society of Echocardiography includes participation from the Canadian Society of Cardiovascular Magnetic Resonance and the Canadian Nuclear and CT Imaging community.
The suggested titles are:
- echo: when to suspect the diagnosis - Francois Tournoux
- cardiac MRI: additional value for the diagnosis - Sarah Blissett
- nuclear imaging: why and when to order it? - Gary Small
- Follow-up and prognosis of cardiac amyloidosis: what are the key imaging parameters? - Margot Davis